Through participation in a government-sponsored multi-year study, researchers at the Comprehensive Cancer Center at Wake Forest University have helped confirm that arsenic trioxide — marketed as Trisenox — significantly improves patient survival when coupled with standard chemotherapy treatment in newly diagnosed patients with acute promyelocytic leukemia, or APL.
Findings from a Phase III study by the Eastern Cooperative Oncology Group (ECOG) were presented yesterday at the American Society of Clinical Oncology (ASCO) meeting in Chicago and demonstrate the impressive survival benefits of using Revlimid (lenalidomide) with reduced doses of the steroid dexamethasone.
A study, led by Dr. Joan Blad?, researcher of the Haematooncology Group of Hospital Cl?nic-IDIBAPS (Barcelona), in collaboration with Dr. Laura Rosi?ol, researcher of the same group, assessed the efficiency in terms of response and survival of autologous bone marrow transplantation in patients suffering from refractory myeloma previously having undergone high-dose chemotherapy (HDT).
A Northwestern University researcher has found a key source of chronic pain appears to be an old memory trace that essentially gets stuck in the prefrontal cortex, the site of emotion and learning. The researcher has identified a drug that controls persistent nerve pain by targeting the part of the brain that experiences the emotional suffering of pain. The drug is D-Cycloserine, which has been used to treat phobic behavior over the past decade.
A clinical trial led and coordinated by Hospital Cl?nic-IDIBAPS, using a drug named Sorafenib, revolutionizes the reality of patients suffering from advanced liver cancer. The results increase overall survival of treated patients by 44 percent in comparison to the control group. The results have been hand selected to be included on the “Best of ASCO” program.
Bayer HealthCare, a subsidiary of Bayer AG (NYSE: BAY), and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced that Nexavar? (sorafenib) tablets significantly extended overall survival in patients with hepatocellular carcinoma (HCC), or primary liver cancer versus those taking placebo by 44%.
GlaxoSmithKline (NYSE: GSK) announced that the European Commission approved its novel topical antibacterial ALTARGO? (retapamulin ointment,1%) for the treatment of impetigo and infected small lacerations, abrasions or sutured wounds.
An Indian HIV positive man is set to return home after being pardoned on humanitarian grounds by judicial authorities here from charges of assaulting a policeman.
Chemotherapy temporarily hinders the body’s immune response, creating a concern that it may interfere with the promising new cancer vaccines being used against brain tumors.
Rats paralyzed due to loss of blood flow to the spine returned to near normal ambulatory function six weeks after receiving grafts of human spinal stem cells (hSSCs), researchers from the University of California, San Diego (UCSD) School of Medicine report.